Randomised controlled trialcited by the Tayebat archiveabstract only checked★ key study A-CHM-16 in-depth review
Early palliative care helps patients with advanced lung cancer
Early palliative care for patients with metastatic non-small-cell lung cancer.
Overview
Temel JS et al.. N Engl J Med 2010 · PMID 20818875 · DOI 10.1056/NEJMoa1000678
Better quality of life, less depression, and longer median survival (11.6 vs 8.9 months) when added to cancer care.
Does the study support the specific claim? Yes · Methodological quality: moderate
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Test early palliative care.
- How was the study done?
RCT.
- How many people, animals or samples were studied?
151 patients.
- What was actually found?
QoL and mood better; survival longer.
- How large was the observed effect?
+2.7 months median (11.6 vs 8.9 months; calculated).
- What do the results mean in everyday life?
Ask early for palliative/supportive care.
- What are the study's limitations?
Small single-centre trial.
- What does it say about Elawady's specific claim?
Supports palliative care, not refusal of oncology.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
That chemotherapy is useless.
Scientific in-depth review
1. Full reference
- Authors
- Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ
- Journal
- N Engl J Med
- Year
- 2010
- Identifier
- PMID 20818875 DOI 10.1056/NEJMoa1000678
- Verification
- verified – PubMed E-utilities efetch, 2026-10-25
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
not stated in abstract
2. Research question
Effect of early palliative care integrated with standard oncologic care in metastatic NSCLC.
3. Study design and population
- Study design
- Randomised controlled trial – Randomised controlled trial
- Population
Ambulatory patients with newly diagnosed metastatic NSCLC
- Country
USA
- Period
not stated in abstract
- Sample size
151 randomised
- Inclusion and exclusion criteria
Newly diagnosed metastatic NSCLC
4. Methods and endpoints
- Exposure / intervention
Early palliative care plus standard oncologic care
- Comparator
Standard oncologic care alone
- Endpoints
Quality of life at 12 weeks (primary); mood; end-of-life care; survival (secondary)
- Statistical methods
Group comparisons
5. Actual results
- Results
FACT-L 98.0 vs 91.5 (P=0.03); depressive symptoms 16% vs 38% (P=0.01); aggressive end-of-life care 33% vs 54% (P=0.05); median survival 11.6 vs 8.9 months (P=0.02).
- Absolute risks
Median survival +2.7 months (11.6 vs 8.9 months; difference calculated)
- Authors' conclusion
Early palliative care improved quality of life and mood; less aggressive end-of-life care but longer survival.
6. Strengths
- Randomised
- Patient-reported outcomes
7. Weaknesses
- Single centre, small
- Survival a secondary outcome
- Unblinded
8. Risk of bias
- Orienting tool
- RoB 2
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- some concerns
- Rationale
Open-label; 27 deaths before 12-week assessment.
9. Assessment of the statistical interpretation
Survival difference is secondary and from a small trial.
10. Relevance to the specific claim
Supports value of palliative care; not evidence against chemotherapy.
11. Independent contrary findings
12. Transferability to Germany and Europe
Moderate.
13. Overall methodological judgement
Correct numbers; framing slightly overstated.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | moderate |
| Risk of bias | some concerns |
| Precision of results | low |
| Directness | direct |
| Reproducibility | partly replicated |
| Consistency with the overall evidence | mixed |
| Regional transferability | moderate |
| Adequacy of the interpretation (by the archive) | essentially correct but incomplete |
14. Open questions
Mechanism of survival effect.
15. Linked fact checks
Use by the Tayebat archive
Note: according to the archive, the studies were compiled by the archive operators. Whether Dr. Elawady himself cited this study is not established.
- What the archive says about the study
Temel (NEJM 2010) proved that early palliative care in metastatic lung cancer improved quality of life and prolonged survival (11.6 vs 8.9 months) despite less aggressive chemotherapy.
- A. What was actually studied?
Adding early palliative care to oncologic care.
- B. What did the authors find?
Better QoL, less depression, longer median survival.
- C. What conclusions do the authors themselves draw?
Early palliative care improves QoL and mood.
- D. What does the archive derive from it?
Less aggressive treatment can be better.
- E. Is this derivation scientifically justified?
Numbers correct. 'Proved' overstates a secondary endpoint; the abstract reports less aggressive end-of-life care, not less chemotherapy in general; both groups received standard oncologic care. It does not support replacing cancer therapy.
- Adequacy of the interpretation (by the archive)
- essentially correct but incomplete